PHIBRO ANIMAL HEALTH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PHIBRO ANIMAL HEALTH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Jun 30, 2021 | $833.35M | Aug 25, 2021 |
| FY2021 | Jun 30, 2020 | $800.35M | Aug 25, 2021 |
| FY2021 | Jun 30, 2019 | $828.00M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $819.98M | Aug 26, 2020 |
| FY2018 | Jun 30, 2017 | $764.28M | Aug 27, 2018 |
| FY2018 | Jun 30, 2016 | $751.53M | Aug 27, 2018 |
| FY2015 | Jun 30, 2015 | $184.95M | Sep 10, 2015 |
| FY2015 | Mar 31, 2015 | $187.50M | Sep 10, 2015 |
| FY2015 | Dec 31, 2014 | $188.69M | Sep 10, 2015 |
| FY2015 | Sep 30, 2014 | $187.46M | Sep 10, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.30B | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $1.02B | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $977.89M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $942.26M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $833.35M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $800.35M | Aug 24, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $399.94M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $313.09M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $298.24M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $285.40M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $271.38M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $256.88M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $264.62M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $266.88M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $248.24M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $239.03M | Aug 27, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $48.26M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $2.42M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $32.61M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $49.18M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $54.39M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $33.55M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $54.71M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $64.88M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $64.62M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $82.73M | Aug 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $110.47M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $53.32M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $71.85M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $78.99M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $74.87M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $69.19M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $83.23M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $98.93M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $97.93M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $85.74M | Aug 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $23.73M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $29.19M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $24.40M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $20.83M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $17.76M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $13.74M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $12.09M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $10.00M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $9.44M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $11.03M | Aug 27, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $289.48M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $259.78M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $226.39M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $206.41M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $196.51M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $187.69M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $181.40M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $167.95M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $150.31M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $153.29M | Aug 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $80.12M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $87.59M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $13.31M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $31.65M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $48.31M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $59.35M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $47.17M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $70.01M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $98.39M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $37.22M | Aug 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.36B | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $982.18M | Aug 27, 2025 |
| FY2024 | Jun 30, 2023 | $971.40M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $931.70M | Aug 30, 2023 |
| FY2022 | Jun 30, 2021 | $841.33M | Aug 24, 2022 |
| FY2021 | Jun 30, 2020 | $784.10M | Aug 25, 2021 |
| FY2020 | Jun 30, 2019 | $726.67M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $671.68M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $623.40M | Aug 27, 2018 |
| FY2017 | Jun 30, 2016 | $607.84M | Aug 30, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.08B | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $725.54M | Aug 27, 2025 |
| FY2024 | Jun 30, 2023 | $688.89M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $669.26M | Aug 30, 2023 |
| FY2022 | Jun 30, 2021 | $602.80M | Aug 24, 2022 |
| FY2021 | Jun 30, 2020 | $595.90M | Aug 25, 2021 |
| FY2020 | Jun 30, 2019 | $510.66M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $486.73M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $472.24M | Aug 27, 2018 |
| FY2017 | Jun 30, 2016 | $517.36M | Aug 30, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $285.68M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $256.64M | Aug 27, 2025 |
| FY2024 | Jun 30, 2023 | $282.51M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $262.44M | Aug 30, 2023 |
| FY2022 | Jun 30, 2021 | $238.53M | Aug 24, 2022 |
| FY2022 | Jun 30, 2020 | $188.20M | Aug 24, 2022 |
| FY2022 | Jun 30, 2019 | $216.02M | Aug 24, 2022 |
| FY2021 | Jun 30, 2018 | $184.95M | Aug 25, 2021 |
| FY2020 | Jun 30, 2017 | $151.16M | Aug 26, 2020 |
| FY2019 | Jun 30, 2016 | $90.48M | Aug 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $59.65M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $54.56M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $53.27M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $53.23M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $52.68M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $52.68M | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | $27.35M | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | $27.35M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $23.98M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $21.12M | Aug 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $272.70M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $243.89M | Aug 27, 2025 |
| FY2024 | Jun 30, 2023 | $260.91M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $247.75M | Aug 30, 2023 |
| FY2022 | Jun 30, 2021 | $218.02M | Aug 24, 2022 |
| FY2021 | Jun 30, 2020 | $183.06M | Aug 25, 2021 |
| FY2020 | Jun 30, 2019 | $168.93M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $131.56M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $82.75M | Aug 27, 2018 |
| FY2017 | Jun 30, 2016 | $33.96M | Aug 30, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $68.04M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $70.61M | Aug 27, 2025 |
| FY2024 | Jun 30, 2023 | $41.28M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $74.25M | Aug 30, 2023 |
| FY2022 | Jun 30, 2021 | $50.21M | Aug 24, 2022 |
| FY2021 | Jun 30, 2020 | $36.34M | Aug 25, 2021 |
| FY2021 | Jun 30, 2019 | $57.57M | Aug 25, 2021 |
| FY2021 | Jun 30, 2018 | $29.17M | Aug 25, 2021 |
| FY2020 | Jun 30, 2017 | $56.08M | Aug 26, 2020 |
| FY2019 | Jun 30, 2016 | $33.61M | Aug 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $312.08M | Aug 28, 2024 |
| FY2024 | Jun 30, 2023 | $333.84M | Aug 28, 2024 |
| FY2023 | Jun 30, 2022 | $287.93M | Aug 30, 2023 |
| FY2014 | Jun 30, 2014 | $286.42M | Sep 18, 2014 |
| FY2014 | Jun 30, 2013 | $297.67M | Sep 18, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 1 | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | 0 | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | 1 | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | 1 | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | 0 | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | 1 | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | 1 | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | 1 | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | 2 | Aug 27, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 1 | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | 0 | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | 1 | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | 1 | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | 0 | Aug 24, 2022 |
| FY2021 | Jun 30, 2019 | 1 | Aug 25, 2021 |
| FY2020 | Jun 30, 2018 | 1 | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | 1 | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | 2 | Aug 27, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Jun 30, 2013 | 30.46M | Sep 18, 2014 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.45M | Aug 27, 2025 |
| FY2025 | Jun 30, 2024 | $19.44M | Aug 27, 2025 |
| FY2025 | Jun 30, 2023 | $19.44M | Aug 27, 2025 |
| FY2024 | Jun 30, 2022 | $19.44M | Aug 28, 2024 |
| FY2023 | Jun 30, 2021 | $19.43M | Aug 30, 2023 |
| FY2022 | Jun 30, 2020 | $19.42M | Aug 24, 2022 |